Top Orphan Drugs: Still a Class Apart? | Evaluate
The lines between orphan drugs and mainstream prescription drugs are blurring. In this infographic, we look at the top orphan drugs and the wider market for drugs for rare diseases.| Evaluate
The lines between orphan drugs and mainstream prescription drugs are blurring. In this infographic, we look at the top orphan drugs and the wider market for drugs for rare diseases.| Evaluate
Orphan drugs for rare diseases are set to make up one fifth of the of all prescription drug sales by 2030. This report investigates the orphan drug landscape out to 2030.| Evaluate
Biotech FDA approvals accounted for two thirds of the 2024 total – a big shift from 2023. We investigate the drivers and challenges for small players going it alone.| Evaluate
2024 Review of Pharma - Analysis of the state of dealmaking, investment & stock price performance of the biopharma sector in 2024| Evaluate
What does 2025 have in store for pharma forecasting teams? We explore the evolving role of forecasting teams in the pharmaceutical industry.| Evaluate
Evaluate’s latest report features 2025 pharma forecasts for top-selling drugs, biggest companies and potential novel drug approvals for the year ahead.| Evaluate
